Correlation between Expression of Estrogen Receptor and Progesterone Receptor and Clinicopathologic Factors in Patients with Primary Breast Cancer_West China Medical Journal

Authors：

 GUOShao-feng ,  WANGXiao-ming , ZHAOJin-hua , YANHao , WUXue-mei , WENLi-jun , DAIWu-zhuang , HUANGYuan

Department of Pathology, People's Hospital of Meishan City, Meishan, Sichuan 620000, P. R. China;

Corresponding author：

WANGXiao-ming, Email: 2318675158@qq.com

Keywords：

Estrogen receptor; Progesterone receptor; Breast cancer; Clinical pathology

DOI：

10.7507/1002-0179.20140013

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the correlation of clinicopathologic factors with the expression of estrogen receptor (ER) and progesterone receptor (PR) in patients with primary breast cancer. Methods The data of 105 patients with primary breast cancer were collected from September 2011 to September 2012. The expression of ER, PR and C-erbB-2 in breast cancer tissues was detected by immunohistochemistry. The correlation between the expression of ER, PR and C-erbB-2 and the clinicopathologic factors was evaluated. Results The positive rates of expression of ER, PR and C-erbB-2 in breast cancer tissues reached 58.1%, 49.5% and 59.0%, respectively. The expression of ER had a positive correlation with the expression of PR. The concordance expression of ER and PR had a negative correlation with the expression of C-erbB-2. The positive rate of expression of ER had a correlation with the lymph node metastasis and histological grading, while it was not correlated with patients' age, the age of menarche, tumor size, tumor position, clinical stages, pathological type, or pathologic morphology of tissue adjacent to cancer (P>0.05). The positive rate of expression of PR and the different positive strength rate of expression of ER were not correlated with clinical and pathological factors (P>0.05). The positive rate of expression of C-erbB-2 in the group with lymph node metastasis was higher than that in non-lymph node metastasis group (P<0.05). Conclusion The expression of ER and PR plays an important role in the occurrence and development of the breast cancer. Joint detection of ER and PR is very important for the evaluation of endocrine therapy effect and prognosis.

Citation： GUOShao-feng, WANGXiao-ming, ZHAOJin-hua, YANHao, WUXue-mei, WENLi-jun, DAIWu-zhuang, HUANGYuan. Correlation between Expression of Estrogen Receptor and Progesterone Receptor and Clinicopathologic Factors in Patients with Primary Breast Cancer. West China Medical Journal, 2014, 29(1): 47-50. doi: 10.7507/1002-0179.20140013 Copy

1.	Yang L, Parkin DM, Ferlay J, et al. Estimates of cancer incidence in China for 2000 and projections for 2005[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(1):243-250.
2.	尹洪芳, 王韫宏, 秦小琪, 等. 新辅助化疗对乳腺癌的组织学分级和生物学指标表达的影响[J]. 中华肿瘤杂志, 2011, 31(11):858-862.
3.	Kurebayashi J. Current clinical trials of endocrine therapy for breast cancer[J]. Breast Cancer, 2007, 14(2):200-214.
4.	王艳, 霍翔, 沈洪兵. 雌激素受体和孕激素受体与乳腺癌关系的研究进展[J]. 中国肿瘤, 2007, 16(12):987-990.
5.	Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer:a validation study[J]. Mod Pathol, 2004, 17(12):1545-1554.
6.	Stendahl M, Rydén L, Nordenskjöld B, et al. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients[J]. Clin Cancer Res, 2006, 12(15):4614-4618.
7.	邓窈窕, 张丽, 蒋明, 等. 乳腺癌患者激素受体、人表皮生长因子受体2表达与免疫组织化学分子亚型分析[J]. 华西医学, 2012, 27(4):491-494.
8.	刘晓光, 徐光炜. C-erbB-2、P53及nm23基因及产物在乳腺癌预后中的意义[J]. 中国肿瘤临床, 1994, 21(5):391-395.
9.	韩晶, 王培军, 汤如勇, 等. HER-2基因在乳腺癌中的表达及其与雌激素受体亚型的关系[J]. 第二军医大学学报, 2006, 27(11):1268-1269.
10.	Stead LA, Lash TL, Sobieraj JE, et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index[J]. Breast Cancer Res, 2009, 11(2):R18.
11.	Ariga R, Zarif A, Korasick J, et al. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma[J]. Breast J, 2005, 11(4):278-280.
12.	李文华, 孙奇, 覃希, 等. ER、PR、C-erbB-2、HMFG在乳腺癌组织中的表达及临床意义[J]. 山东医药, 2011, 51(47):54-56.
13.	郭丽英, 郭晨明, 马方婧, 等. 乳腺癌雌激素受体表达和临床病理因素的关系[J]. 新疆医科大学学报, 2009, 32(1):48-50.
14.	胡应光. 乳腺癌ER、PR、P53、C-erbB-2表达的临床意义[J]. 中国基层医药, 2007, 14(6):941-942.
15.	姚卫康, 包建英, 吴德明, 等. C-erbB-2、ER、PR在乳腺癌中的表达及其临床意义[J]. 苏州大学学报·医学版, 2007, 27(4):569-571.
16.	阚秀, 沈丹华, 史斌, 等. 关于乳腺普通性增生、不典型增生和原位癌相互关系及鉴别诊断的探讨[J]. 中华病理学杂志, 2004, 33(4):14-17.
17.	李金锋, 郑德清. 乳腺浸润癌癌前病变的研究现状[J]. 国外医学·肿瘤学分册, 2002, 29(3):213-216.

1. Yang L, Parkin DM, Ferlay J, et al. Estimates of cancer incidence in China for 2000 and projections for 2005[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(1):243-250.
2. 尹洪芳, 王韫宏, 秦小琪, 等. 新辅助化疗对乳腺癌的组织学分级和生物学指标表达的影响[J]. 中华肿瘤杂志, 2011, 31(11):858-862.
3. Kurebayashi J. Current clinical trials of endocrine therapy for breast cancer[J]. Breast Cancer, 2007, 14(2):200-214.
4. 王艳, 霍翔, 沈洪兵. 雌激素受体和孕激素受体与乳腺癌关系的研究进展[J]. 中国肿瘤, 2007, 16(12):987-990.
5. Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer:a validation study[J]. Mod Pathol, 2004, 17(12):1545-1554.
6. Stendahl M, Rydén L, Nordenskjöld B, et al. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients[J]. Clin Cancer Res, 2006, 12(15):4614-4618.
7. 邓窈窕, 张丽, 蒋明, 等. 乳腺癌患者激素受体、人表皮生长因子受体2表达与免疫组织化学分子亚型分析[J]. 华西医学, 2012, 27(4):491-494.
8. 刘晓光, 徐光炜. C-erbB-2、P53及nm23基因及产物在乳腺癌预后中的意义[J]. 中国肿瘤临床, 1994, 21(5):391-395.
9. 韩晶, 王培军, 汤如勇, 等. HER-2基因在乳腺癌中的表达及其与雌激素受体亚型的关系[J]. 第二军医大学学报, 2006, 27(11):1268-1269.
10. Stead LA, Lash TL, Sobieraj JE, et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index[J]. Breast Cancer Res, 2009, 11(2):R18.
11. Ariga R, Zarif A, Korasick J, et al. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma[J]. Breast J, 2005, 11(4):278-280.
12. 李文华, 孙奇, 覃希, 等. ER、PR、C-erbB-2、HMFG在乳腺癌组织中的表达及临床意义[J]. 山东医药, 2011, 51(47):54-56.
13. 郭丽英, 郭晨明, 马方婧, 等. 乳腺癌雌激素受体表达和临床病理因素的关系[J]. 新疆医科大学学报, 2009, 32(1):48-50.
14. 胡应光. 乳腺癌ER、PR、P53、C-erbB-2表达的临床意义[J]. 中国基层医药, 2007, 14(6):941-942.
15. 姚卫康, 包建英, 吴德明, 等. C-erbB-2、ER、PR在乳腺癌中的表达及其临床意义[J]. 苏州大学学报·医学版, 2007, 27(4):569-571.
16. 阚秀, 沈丹华, 史斌, 等. 关于乳腺普通性增生、不典型增生和原位癌相互关系及鉴别诊断的探讨[J]. 中华病理学杂志, 2004, 33(4):14-17.
17. 李金锋, 郑德清. 乳腺浸润癌癌前病变的研究现状[J]. 国外医学·肿瘤学分册, 2002, 29(3):213-216.

West China Medical Journal

Correlation between Expression of Estrogen Receptor and Progesterone Receptor and Clinicopathologic Factors in Patients with Primary Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content